Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation.

[1]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[2]  A. Ganser,et al.  CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. , 2013, Blood.

[3]  B. Sandmaier,et al.  CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. , 2013, Blood.

[4]  A. Ganser,et al.  Donor Vδ1+ γδ T cells expand after allogeneic hematopoietic stem cell transplantation and show reactivity against CMV-infected cells but not against progressing B-CLL , 2013, Experimental Hematology & Oncology.

[5]  B. Djulbegovic,et al.  Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review , 2012, Leukemia.

[6]  L. Lanier,et al.  Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. , 2012, Blood.

[7]  R. Fanin,et al.  Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients , 2012, Leukemia.

[8]  F. Locatelli,et al.  Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? , 2012, Blood.

[9]  S. Schnittger,et al.  Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. , 2011, Blood.

[10]  A. Pettitt,et al.  Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. , 2010, Blood.

[11]  M. Boeckh,et al.  How we treat cytomegalovirus in hematopoietic cell transplant recipients. , 2009, Blood.

[12]  A. Levis,et al.  Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. , 2008, Blood.

[13]  Jeffrey S. Miller,et al.  Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  M. Maris,et al.  Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2007, Blood.

[15]  R. Fanin,et al.  Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome , 2007, Leukemia.

[16]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Sorror,et al.  Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  Michael Boeckh,et al.  The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. , 2004, Blood.

[20]  G. Papanicolaou,et al.  Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  A. Nagler,et al.  Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma , 2003, Bone Marrow Transplantation.

[22]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[23]  H. Einsele,et al.  Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors , 2001, The Lancet.

[24]  A. Elmaagacli,et al.  Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT , 2000, Bone Marrow Transplantation.

[25]  D. Weisenburger,et al.  Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. , 1992, Blood.

[26]  N. Keiding,et al.  Graft‐versus‐leukaemia activity associated with cytomegalovirus seropositive bone marrow donors but separated from graft‐versus‐host disease in allograft recipients with AML , 1987, European journal of haematology.

[27]  G. Gahrton,et al.  Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection , 1986, British journal of haematology.

[28]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[29]  D. Baarle,et al.  γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia , 2013, Leukemia.

[30]  A. Gratwohl.  Principles of conditioning , 2008 .

[31]  A. Pileri,et al.  Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. , 2002, Blood.

[32]  O. Ringdén,et al.  Early leukemia, seropositivity for several herpes viruses and chronic graft-versus-host disease are associated with decreased incidence of relapse after allogenic bone marrow transplantation , 1991 .